Recent reports demonstrate that recurrent mutations in NFKB2 are drivers for CLL progression [13,14], and in the case of MCL, resistance to ibrutinib is defined by aberrant non-canonical NF-κB signalling due to mutations in TRAF2 or BIRC3 [11]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.